CING
Cingulate Inc.
Healthcare — Biotechnology
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Price History
Fundamentals
| Market Cap | $79.33M |
| P/E Ratio (TTM) | - |
| Forward P/E | -7.96 |
| EPS (TTM) | $-4.33 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -225.11% |
| Debt/Equity | 39.38 |
| Recommendation | Strong Buy 1.3 |
| Analyst Target | $23.00 |
| Analysts | 5 |
| Next Earnings | - |
| Indexes | - |
Technical Indicators
| RSI (14) | 69.8 |
| Beta | -0.85 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $11.89 |
| 52-Week Low | $3.16 |
| 50-Day Avg | $4.88 |
| 200-Day Avg | $5.00 |
| Avg Volume | 563.2K |
| Volume | 388.2K |
Performance Analysis
BULLISHCING shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:03 UTC
Back to Screener Export Report